Sign in or create an account to add this stock to your watchlist.
About Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700
Debt
Debt-to-Equity RatioN/A
Current Ratio11.47
Quick Ratio11.47
Price-To-Earnings
Trailing P/E Ratio-6.59
Forward P/E Ratio-5.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$910,000.00
Price / Sales440.55
Cash FlowN/A
Price / CashN/A
Book Value$2.20 per share
Price / Book5.57
Profitability
EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-57.40%
Return on Assets-52.21%
Miscellaneous
Employees37
Outstanding Shares32,700,000
Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions
What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics (NASDAQ:CARA) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.04. View Cara Therapeutics' Earnings History.
What price target have analysts set for CARA?
12 brokers have issued 1-year price targets for Cara Therapeutics' shares. Their predictions range from $17.00 to $31.50. On average, they anticipate Cara Therapeutics' stock price to reach $25.1923 in the next twelve months. View Analyst Ratings for Cara Therapeutics.
What are Wall Street analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/21/2018)
- 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Endo International (ENDP), TherapeuticsMD (TXMD), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), Myovant Sciences (MYOV) and Mallinckrodt (MNK).
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the folowing people:
- Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
- Dr. Frédérique Menzaghi Ph.D., Sr. VP of R&D (Age 52)
- Dr. Joseph Stauffer D.O., M.B.A., Chief Medical Officer (Age 52)
- Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
- Dr. Mani Mohindru, Chief Financial Officer (Age 46)
Has Cara Therapeutics been receiving favorable news coverage?
Media coverage about CARA stock has trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cara Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Cara Therapeutics' major shareholders?
Cara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.61%), Nexthera Capital LP (1.07%), ETF Managers Group LLC (1.03%), JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.71%) and UBS Group AG (0.55%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.
Which institutional investors are selling Cara Therapeutics stock?
CARA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Tiverton Asset Management LLC, C WorldWide Group Holding A S, JPMorgan Chase & Co. and Stifel Financial Corp. Company insiders that have sold Cara Therapeutics company stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.
Which institutional investors are buying Cara Therapeutics stock?
CARA stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, ETF Managers Group LLC, UBS Group AG, Wells Fargo & Company MN, LPL Financial LLC, DekaBank Deutsche Girozentrale, Commonwealth Equity Services LLC and Swiss National Bank. View Insider Buying and Selling for Cara Therapeutics.
How do I buy shares of Cara Therapeutics?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cara Therapeutics' stock price today?
One share of CARA stock can currently be purchased for approximately $12.26.
How big of a company is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $400.90 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.
How can I contact Cara Therapeutics?
Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.
MarketBeat Community Rating for Cara Therapeutics (CARA)
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cara Therapeutics (NASDAQ:CARA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Cara Therapeutics in the last 12 months. Their average twelve-month price target is $25.1923, suggesting that the stock has a possible upside of 105.48%. The high price target for CARA is $31.50 and the low price target for CARA is $17.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.85 | 2.85 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.1923 | $25.4643 | $26.0357 | $26.1923 |
| Price Target Upside: | 105.48% upside | 106.69% upside | 111.67% upside | 116.47% upside |
Cara Therapeutics (NASDAQ:CARA) Consensus Price Target History
Cara Therapeutics (NASDAQ:CARA) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Cara Therapeutics (NASDAQ:CARA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cara Therapeutics (NASDAQ CARA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 52.80%
Cara Therapeutics (NASDAQ CARA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/16/2018 | Derek T Chalmers | CEO | Sell | 5,400 | $15.00 | $81,000.00 | 1,071,392 |  |
| 2/15/2018 | Frederique Ph.D. Menzaghi | SVP | Sell | 3,000 | $15.02 | $45,060.00 | 119,000 | |
| 1/24/2018 | Derek T Chalmers | CEO | Sell | 12,500 | $15.00 | $187,500.00 | 1,073,792 | |
| 1/24/2018 | Frederique Ph.D. Menzaghi | SVP | Sell | 15,000 | $15.00 | $225,000.00 | 122,000 | |
| 11/1/2017 | Derek T Chalmers | CEO | Sell | 16,000 | $12.66 | $202,560.00 | 1,066,292 | |
| 7/14/2017 | Derek T Chalmers | CEO | Sell | 25,000 | $15.05 | $376,250.00 | 1,107,292 | |
| 7/14/2017 | Frederique Ph.D. Menzaghi | VP | Sell | 3,000 | $15.00 | $45,000.00 | 120,000 | |
| 6/29/2017 | Dean Slagel | Director | Sell | 250,000 | $25.87 | $6,467,500.00 | | |
| 3/31/2017 | Ventures Vi Lp Rho | Major Shareholder | Buy | 500,000 | $18.19 | $9,095,000.00 | | |
| 4/20/2016 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $9.00 | $54,000.00 | 123,000 | |
| 3/17/2016 | Ventures Vi Lp Rho | Major Shareholder | Buy | 400,000 | $4.87 | $1,948,000.00 | | |
| 2/3/2016 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $9.04 | $54,240.00 | 129,000 | |
| 1/26/2016 | Michael E Lewis | Insider | Sell | 7,262 | $10.93 | $79,373.66 | 314,988 | |
| 1/6/2016 | Derek T Chalmers | CEO | Sell | 12,500 | $17.22 | $215,250.00 | 1,087,292 | |
| 12/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $16.21 | $97,260.00 | 141,000 | |
| 11/2/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $14.26 | $85,560.00 | 147,000 | |
| 10/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 6,000 | $13.95 | $83,700.00 | 153,000 | |
| 9/1/2015 | Frederique Ph.D. Menzaghi | VP | Sell | 7,000 | $18.63 | $130,410.00 | 159,000 | |
| 8/18/2015 | Josef Schoell | CFO | Buy | 3,000 | $22.10 | $66,300.00 | 28,000 | |
| 6/1/2015 | Michael E Lewis | Insider | Sell | 7,262 | $9.50 | $68,989.00 | | |
| 5/19/2015 | Dean Slagel | Director | Sell | 188,811 | $10.02 | $1,891,886.22 | | |
| 4/1/2015 | Michael E Lewis | Insider | Sell | 7,262 | $9.90 | $71,893.80 | | |
| 3/2/2015 | Michael E Lewis | Insider | Sell | 7,262 | $10.11 | $73,418.82 | | |
| 2/2/2015 | Michael E Lewis | Insider | Sell | 7,262 | $10.60 | $76,977.20 | | |
| 2/5/2014 | Ventures Vi Lp Rho | Major Shareholder | Buy | 225,818 | $11.00 | $2,483,998.00 | | |
(Data available from 1/1/2013 forward)
Cara Therapeutics (NASDAQ CARA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Better Marijuana Stock: Insys Pharmaceuticals vs. Cara Therapeutics
www.msn.com - May 19 at 3:03 PM |
 | Forget Cara Therapeutics' Earnings -- Here's the Real News
finance.yahoo.com - May 17 at 3:11 PM |
 | Forget Cara Therapeutics' Earnings -- Here's the Real News
www.fool.com - May 17 at 1:40 PM |
 | Global Marijuana Industry 2018 – Market Size, Analysis, Share, Research, Growth and Forecast
www.marketwatch.com - May 17 at 5:40 AM |
| Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting
finance.yahoo.com - May 15 at 5:20 AM |
| Edited Transcript of CARA earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 15 at 5:20 AM |
 | Cara Therapeutics (CARA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 5:37 AM |
| Research Analysts Set Expectations for Cara Therapeutics' Q2 2018 Earnings (CARA)
www.americanbankingnews.com - May 14 at 2:38 AM |
| Cara Therapeutics (CARA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 11 at 8:04 PM |
| Cara Therapeutics (CARA) Releases Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 11 at 1:53 PM |
 | Cara Therapeutics' (CARA) CEO Derek Chalmers on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM |
| Cara Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 5:01 AM |
| Cara: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:01 AM |
| Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - May 3 at 5:13 AM |
| Edited Transcript of CARA earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 1 at 3:02 PM |
| 4/20: Marijuana, hemp legalization moves ahead in many states
finance.yahoo.com - April 22 at 3:02 PM |
| Cara Therapeutics (CARA) Stock Rating Lowered by Vetr
www.americanbankingnews.com - April 20 at 5:18 PM |
| Vetr Upgrades Cara Therapeutics (CARA) to "Buy"
www.americanbankingnews.com - April 20 at 11:19 AM |
| Vetr Upgrades Cara Therapeutics (CARA) to "Strong-Buy"
www.americanbankingnews.com - April 20 at 10:45 AM |
| Cara Therapeutics (CARA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:55 AM |
| Cara Therapeutics (CARA) Downgraded by BidaskClub
www.americanbankingnews.com - April 15 at 12:04 AM |
| Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
finance.yahoo.com - April 10 at 3:01 PM |
| Needham & Company LLC Reiterates "Buy" Rating for Cara Therapeutics (CARA)
www.americanbankingnews.com - April 7 at 11:00 PM |
| Here's Why Cara Therapeutics Slipped 11.4% in March
www.msn.com - April 6 at 3:14 PM |
| Here's Why Cara Therapeutics Slipped 11.4% in March
finance.yahoo.com - April 6 at 3:14 PM |
| Should You Be Concerned About Cara Therapeutics Inc’s (NASDAQ:CARA) Earnings Growth?
finance.yahoo.com - April 4 at 4:43 PM |
| Cara Therapeutics (CARA) Price Target Cut to $24.00 by Analysts at CIBC
www.americanbankingnews.com - April 1 at 2:38 PM |
| Cara Therapeutics (CARA) Price Target Raised to $26.00
www.americanbankingnews.com - April 1 at 2:38 PM |
| Cara Therapeutics (CARA) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - April 1 at 2:38 PM |
| Don't Get Greedy With Cara Therapeutics, Inc. Stock
www.msn.com - March 28 at 3:03 PM |
| Don't Get Greedy With Cara Therapeutics, Inc. Stock
finance.yahoo.com - March 28 at 3:03 PM |
| Cara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 25 at 5:36 AM |
| BidaskClub Downgrades Cara Therapeutics (CARA) to Sell
www.americanbankingnews.com - March 24 at 1:54 PM |
| Cara Therapeutics' (CARA) "Buy" Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - March 22 at 8:12 PM |
| Zacks Investment Research Upgrades Cara Therapeutics (CARA) to Hold
www.americanbankingnews.com - March 21 at 7:16 PM |
| Cramer's lightning round: With so many great bank stocks,...
finance.yahoo.com - March 21 at 5:04 AM |
| Cramer's lightning round: With so many great bank stocks, stay away from Wells Fargo
finance.yahoo.com - March 21 at 5:04 AM |
| Cara Therapeutics (CARA) Given a $22.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 5:02 PM |
| 3 High-Risk, High-Reward Marijuana Stocks
finance.yahoo.com - March 19 at 3:04 PM |
| Cara Therapeutics Inc (NASDAQ:CARA): When Will It Breakeven?
finance.yahoo.com - March 16 at 3:02 PM |
| Edited Transcript of CARA earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 3:02 PM |
| Cara Therapeutics (CARA) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 16 at 9:28 AM |
 | Cara Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 5:02 AM |
| Cara Therapeutics' (CARA) CEO Derek Chalmers on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 5:02 AM |
 | After-Hours Earnings Report for March 15, 2018 : ADBE, AVGO, ULTA, JBL, OSTK, REV, REI, FSM, GDEN, CBAY ... - Nasdaq
www.nasdaq.com - March 15 at 3:13 PM |
 | Form 4 Cara Therapeutics, Inc. For: Mar 09 Filed by: Terrillion Scott - StreetInsider.com
www.streetinsider.com - March 14 at 3:11 PM |
| Premarket analyst action - healthcare - Cara Therapeutics Inc ... - Seeking Alpha
seekingalpha.com - March 13 at 5:08 AM |
| Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 - GlobeNewswire (press release)
globenewswire.com - March 9 at 5:07 AM |
| Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
finance.yahoo.com - March 9 at 5:07 AM |
 | Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of ... - PR Newswire (press release)
www.prnewswire.com - March 1 at 3:03 PM |
Cara Therapeutics (NASDAQ:CARA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cara Therapeutics (NASDAQ:CARA) Income Statement, Balance Sheet and Cash Flow Statement
Cara Therapeutics (NASDAQ CARA) Stock Chart for Sunday, May, 20, 2018
Loading chart…
